Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Old Port Advisors

Old Port Advisors reduced its position in Moderna, Inc. (NASDAQ:MRNA) by 4.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,576 shares of the company’s stock after selling 610 shares during the period. Old Port Advisors’ holdings in Moderna were worth $523,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in MRNA. Intrinsic Value Partners LLC boosted its stake in shares of Moderna by 91.1% during the 3rd quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after acquiring an additional 24,505 shares in the last quarter. Banco Santander S.A. purchased a new position in Moderna during the third quarter worth approximately $3,550,000. John G Ullman & Associates Inc. boosted its position in Moderna by 341.3% during the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after purchasing an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in Moderna by 11.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock valued at $107,885,000 after purchasing an additional 167,596 shares during the period. Finally, Vontobel Holding Ltd. increased its position in shares of Moderna by 148.2% in the third quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company’s stock valued at $7,758,000 after buying an additional 69,313 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,379 shares of company stock worth $158,195 over the last ninety days. Corporate insiders own 15.70% of the company’s stock.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research analyst reports. Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a research report on Thursday, September 19th. The Goldman Sachs Group reduced their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Friday, November 8th. Finally, Sanford C. Bernstein initiated coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price for the company. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $79.50.

Moderna Trading Up 3.7 %

MRNA traded up $1.55 on Thursday, hitting $43.13. The company had a trading volume of 1,843,017 shares, compared to its average volume of 5,139,064. The company’s fifty day moving average price is $44.06 and its 200 day moving average price is $73.87. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a market cap of $16.60 billion, a P/E ratio of -7.41 and a beta of 1.58.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the business earned ($1.39) earnings per share. As a group, equities analysts expect that Moderna, Inc. will post -9.3 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.